efimosfermin alfa clinical trial intelligence

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease is a PHASE1 clinical asset sponsored by GlaxoSmithKline in Non-alcoholic Fatty Liver Disease. SEO and diligence focus: Efimosfermin alfa, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by target_normalized: Efimosfermin alfa